---
title: "Viking Therapeutics tumbles 8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305708416.md"
description: "Viking Therapeutics fell 8.08% to US$26.86. Down 23.65% YTD."
datetime: "2026-11-16T18:19:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305708416.md)
  - [en](https://longbridge.com/en/news/305708416.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305708416.md)
generator: "portal-rs"
---

# Viking Therapeutics tumbles 8%

Viking Therapeutics (VKTX.US) tumbled more than **8%** during regular trading to **$26.86**.

The stock is down 23.65% year to date and sits 37.68% below its 52-week high of US$43.10.

The Nasdaq Composite is down 2.67% over the past five sessions and up 5.75% year to date.

The company reported zero revenue for the third quarter of 2026, with a loss per share of $1.55, wider than the IBES consensus of $1.07. Net loss widened to $183.2 million, while operating expenses surged nearly 90% year-over-year to $187.1 million, driven primarily by the expansion of Phase 3 clinical trials for its obesity drug VK2735.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)

## Related News & Research

- [Viking Therapeutics (VKTX) Stock Trades At A Premium To Book Value](https://longbridge.com/en/news/306273528.md)
- [VKTX: VK2735 showed durable weight loss on less-frequent dosing; Phase 3 readouts lie ahead](https://longbridge.com/en/news/305922449.md)
- [Viking Therapeutics (VKTX) Could Be 77% Undervalued As VK2735 Obesity Data Draws Focus](https://longbridge.com/en/news/305696719.md)
- [Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial](https://longbridge.com/en/news/305578038.md)
- [Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 | VKTX Stock News](https://longbridge.com/en/news/305578185.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**